1-4 of 4
C. Willemien Menke-van der Houven van Oordt
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

[18F]FDG and [18F]FES PET/CT Imaging as a Biomarker for Therapy Effect in Patients with Metastatic ER+ Breast Cancer Undergoing Treatment with Rintodestrant

Ramsha Iqbal, Maqsood Yaqub, Huseyyin O. Bektas, Daniela E. Oprea-Lager, Elisabeth G.E. de Vries, Andor W.J.M. Glaudemans, Philippe Aftimos, Géraldine Gebhart, Andrew P. Beelen, Robert C. Schuit, Albert D. Windhorst, Ronald Boellaard, C. Willemien Menke-van der Houven van Oordt
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (11): 2075–2084.
https://doi.org/10.1158/1078-0432.CCR-22-2720
Published: 01 June 2023
View article titled, [<sup>18</sup>F]FDG and [<sup>18</sup>F]FES PET/CT Imaging as a Biomarker for Therapy Effect in Patients with Metastatic ER+ Breast Cancer Undergoing Treatment with Rintodestrant
Open the PDF for [<sup>18</sup>F]FDG and [<sup>18</sup>F]FES PET/CT Imaging as a Biomarker for Therapy Effect in Patients with Metastatic ER+ Breast Cancer Undergoing Treatment with Rintodestrant in another window
Includes: Supplementary data
Journal Articles

[89Zr]Zr-DFO-girentuximab and [18F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma

Sarah R. Verhoeff, Sjoukje F. Oosting, Sjoerd G. Elias, Suzanne C. van Es, Sophie L. Gerritse, Lindsay Angus, Sandra Heskamp, Ingrid M.E. Desar, C. Willemien Menke-van der Houven van Oordt, Astrid A.M. van der Veldt, Anne I.J. Arens, Adrienne H. Brouwers, Bertha Eisses, Peter F.A. Mulders, Otto S. Hoekstra, Gerben J.C. Zwezerijnen, Winette T.A. van der Graaf, Erik H.J.G. Aarntzen, Wim J.G. Oyen, Carla M.L. van Herpen
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (3): 592–601.
https://doi.org/10.1158/1078-0432.CCR-22-0921
Published: 01 February 2023
View article titled, [<sup>89</sup>Zr]Zr-DFO-girentuximab and [<sup>18</sup>F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma
Open the PDF for [<sup>89</sup>Zr]Zr-DFO-girentuximab and [<sup>18</sup>F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

Praluzatamab Ravtansine, a CD166-Targeting Antibody–Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial

Valentina Boni, Mary J. Fidler, Hendrik-Tobias Arkenau, Alexander Spira, Funda Meric-Bernstam, Nataliya Uboha, Rachel E. Sanborn, Randy F. Sweis, Patricia LoRusso, Misako Nagasaka, Javier Garcia-Corbacho, Shadia Jalal, James J. Harding, Stella K. Kim, Iris H.C. Miedema, Danielle J. Vugts, Marc C. Huisman, Gerben J.C. Zwezerijnen, Guus A.M.S. van Dongen, C. Willemien Menke van der Houven van Oordt, Song Wang, Tam Dang, Ivan A. Zein, Olga Vasiljeva, Susan K. Lyman, Virginia Paton, Alison Hannah, Joyce F. Liu
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (10): 2020–2029.
https://doi.org/10.1158/1078-0432.CCR-21-3656
Published: 13 May 2022
View article titled, Praluzatamab Ravtansine, a CD166-Targeting Antibody–Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial
Open the PDF for Praluzatamab Ravtansine, a CD166-Targeting Antibody–Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial in another window
Includes: Supplementary data
Journal Articles

89Zr-labeled Bispecific T-cell Engager AMG 211 PET Shows AMG 211 Accumulation in CD3-rich Tissues and Clear, Heterogeneous Tumor Uptake

Kirsten L. Moek, Stijn J.H. Waaijer, Iris C. Kok, Frans V. Suurs, Adrienne H. Brouwers, C. Willemien Menke-van der Houven van Oordt, Thijs T. Wind, Jourik A. Gietema, Carolien P. Schröder, Shekar V.K. Mahesh, Annelies Jorritsma-Smit, Marjolijn N. Lub-de Hooge, Rudolf S.N. Fehrmann, Derk Jan A. de Groot, Elisabeth G.E. de Vries
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (12): 3517–3527.
https://doi.org/10.1158/1078-0432.CCR-18-2918
Published: 14 June 2019
View article titled, <sup>89</sup>Zr-labeled Bispecific T-cell Engager AMG 211 PET Shows AMG 211 Accumulation in CD3-rich Tissues and Clear, Heterogeneous Tumor Uptake
Open the PDF for <sup>89</sup>Zr-labeled Bispecific T-cell Engager AMG 211 PET Shows AMG 211 Accumulation in CD3-rich Tissues and Clear, Heterogeneous Tumor Uptake in another window
Includes: Supplementary data